Giancarlo Silvio Marenzi
@ccfm.it
Cardiologico Monzino
Scopus Publications
- Percutaneous coronary intervention in nonagenarians with acute myocardial infarction: a 15-year population-based study
Giancarlo Marenzi, Nicola Cosentino, Daniela Mele, Filippo Trombara, Giampaolo D’Aleo, et al.
Scientific Reports, 2026 - Severe obesity and in-hospital outcomes in acute myocardial infarction: Insights into the role of systemic inflammation
Nicola Cosentino, Letizia Velato, Alice Bonomi, Chiara Morocutti, Filippo Trombara, et al.
International Journal of Cardiology, 2026 - Prognostic Impact of Cancer in Patients Hospitalized for Acute Myocardial Infarction: A Population-Based Cohort Study
Nicola Cosentino, Filippo Trombara, Matteo Franchi, Daniela Cardinale, Alice Bonomi, et al.
Journal of Clinical Medicine, 2026
Background: Cancer is common among patients with acute myocardial infarction (AMI) and may influence management and outcomes. The prognostic impact of cancer status (active vs. past) and its anatomical site remains insufficiently defined. We evaluated the association between cancer and short- and long-term outcomes after AMI in a large population cohort. Methods: Using linked administrative databases from Lombardy, Italy, we identified adults with a first AMI hospitalization from 2014 to 2022 (N = 124,403). Patients were categorized by cancer history, cancer status (active vs. past), and cancer site. The primary endpoint was in-hospital mortality; secondary endpoints were 1-year all-cause mortality and 1-year rehospitalization for AMI or acute heart failure (AHF). Multivariable log-binomial, Cox, and Fine&Gray models were applied. Results: Overall, 18,463 (14.8%) had a history of cancer. They were older and had higher comorbidity burden. Cancer history was associated with higher in-hospital mortality (adjusted risk ratio [RR] 1.06, 95% CI 0.99–1.13) and one-year mortality (adjusted hazard ratio [HR] 1.46, 95% CI 1.40–1.52). Active cancer carried the greatest risk (in-hospital RR 1.07, 95% CI 1.00–1.15; 1-year HR 1.60, 95% CI 1.53–1.68), whereas past cancer showed no excess mortality. Site-specific analyses identified lung (one-year HR 2.69, 95% CI 2.15–3.37) and hematological cancers (one-year HR 2.19, 95% CI 1.88–2.56) as highest-risk. Elevated mortality with cancer was consistent in STEMI and NSTEMI. Competing-risk analyses showed a similar risk of rehospitalization among cancer and non-cancer patients. Conclusions: In a real-world, unselected AMI population, cancer worsens short- and long-term survival, especially when active and involving the lungs or the hematopoietic tissues. Incorporating cancer status into AMI risk stratification and strengthening cardio-oncology pathways in acute care are warranted to improve patient outcomes. - Weekly and seasonal patterns of acute myocardial infarction in patients with and without diabetes mellitus: A population-based study
Nicola Cosentino, Alice Bonomi, Stefano Genovese, Chiara Molinari, Olivia Leoni, et al.
Nutrition Metabolism and Cardiovascular Diseases, 2026 - Prognostic significance implications of aortic valve sclerosis in the development of aortic stenosis: a systematic review and meta-analysis
Veronika A Myasoedova, Vincenza Valerio, Ilaria Massaiu, Francesca Bertolini, Valentina Rusconi, et al.
Open Heart, 2026
Background Fibrocalcific aortic valve sclerosis (AVSc), the earliest manifestation of aortic stenosis (AS), is increasingly recognised as a marker of systemic vascular damage and adverse cardiovascular outcomes. While a subset of AVSc patients progresses to AS, reported rates vary widely. We conducted a systematic review and meta-analysis to better define the natural history of AVSc progression. Methods Following Preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, we searched PubMed, Scopus and Web of Science through July 2025 for observational studies reporting AS development in AVSc patients. Primary outcomes were progression to any degree of AS and to severe AS. Pooled event rates were calculated using a random-effects model. Heterogeneity and publication bias were assessed using standard statistical methods. Meta-regression explored associations with clinical and demographic variables. Results Eight studies (n=12 388 patients) reported on the progression of AVSc patients to any AS stage, and nine studies (n=19 486 patients) on the progression to severe AS. Over a median follow-up of 4.0 years, 14.1% of AVSc patients progressed to any AS stage (effect size: 0.14; 95% CI 0.02 to 0.53), and 2.0% to severe AS (effect size: 0.02; 95% CI 0.003 to 0.094). Heterogeneity was high, but no publication bias was detected. Meta-regression found no significant predictors of progression. Conclusions Approximately one in six AVSc patients progresses to AS within 4 years, and 2% develop a severe disease. These findings underscore the importance of structured echocardiographic surveillance and support AVSc as a clinically relevant marker of systemic cardiovascular risk. - Hypoglycemia and glycemic variability in acute myocardial infarction: the lesser-known aspects of glycemic control
Claudia Lucci, Alessandro Marongiu, Stefano Genovese, Mario Mazza, Nicola Cosentino, et al.
Cardiovascular Diabetology, 2025 - Non-stenotic fibro-calcific aortic valve as a predictor of myocardial infarction recurrence
Veronika A Myasoedova, Mattia Chiesa, Nicola Cosentino, Alice Bonomi, Monica Ludergnani, et al.
European Journal of Preventive Cardiology, 2025
Aims Patients with acute myocardial infarction (AMI) are at increased risk of recurrent cardiovascular events. Non-stenotic aortic valve fibro-calcific remodelling (called aortic valve sclerosis; AVSc), reflecting systemic damage, may serve as a new marker of risk. This study aims to stratify subgroups of AMI patients with specific probabilities of recurrent AMI and to evaluate the importance of AVSc in this setting. Methods and results Consecutive AMI patients (n = 2530) were admitted at Centro Cardiologico Monzino (2010–19) and followed up for 5 years. Patients were divided into study (n = 1070) and test (n = 966) cohorts. Topological data analysis (TDA) was used to stratify patient subgroups, while Kaplan–Meier and Cox regression analyses were used to evaluate the significance of baseline characteristics. Topological data analysis identified 11 subgroups of AMI patients with specific baseline characteristics. Two subgroups showed the highest rate of re-infarction after 5 years from the indexed AMI with a combined hazard ratio (HR) of 3.8 [95% confidence interval (CI): 2.7–5.4] compared with the other subgroups. This was confirmed in the test cohort (HR = 3.1; 95% CI: 2.2–4.3). These two subgroups were mostly men, with hypertension and dyslipidaemia, who exhibit a higher prevalence of AVSc, higher levels of high-sensitive C-reactive protein and creatinine. In the year-by-year analysis, AVSc, adjusted for all confounders, showed an independent association with the increased risk of re-infarction (odds ratio of ∼2 at all time points), in both the study and the test cohorts (all P < 0.01). Conclusion AVSc is a crucial variable for identifying AMI patients at high risk of recurrent AMI and its presence should be considered when assessing the management of AMI patients. The inclusion of AVSc in risk stratification models may improve the accuracy of predicting the likelihood of recurrent AMI, leading to more personalized treatment decisions. - Impact of glomerular filtration rate estimation formulas on MECKI score performance and prognostic accuracy in heart failure: The MECKI-RENAL study
Massimo Mapelli, Elisabetta Salvioni, Nicola Cosentino, Francesca Pluchinotta, Arianna Galotta, et al.
European Heart Journal Quality of Care and Clinical Outcomes, 2025
Aims Appropriate interpretation of kidney function is essential for clinical and therapeutic management of heart failure (HF). We evaluated the prognostic accuracy of 6 glomerular filtration rate estimation (eGFR) formulas in HF patients with reduced ejection fraction (HFrEF) and their impact on the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score prognostic accuracy. Methods and results We retrospectively analyzed 6933 patients enrolled in the MECKI score database. GFR was estimated using Modification of Diet in Renal Disease (MDRD); MRDR modified (MDRDm); Cockcroft-Gault (CG), CG modified (CGm); Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and the European Kidney Function Consortium (EKFC). Survival was assessed as the composite of cardiovascular death, left ventricular assist device implantation and urgent heart transplantation at 2 years. Each GFR estimation demonstrated similar but moderate prognostic capacity, with the area under the curve (AUC) for predicting survival ranging from 0.6271 (EKFC) to 0.635 (MDRD). For cardiovascular death, the AUC values ranged from 0.668 to 0.677. The prevalence of severe CKD, defined as eGFR <30 mL/min/1.73 m², ranged from 3.2% (MDRD) to 4.5% (EKFC). When included in MECKI score, the 6 formulas showed a MECKI AUC for prognosis ranging from 0.7841 to 0.7883, with the EKFC and CKD-EPI showing the best performance. Conclusion GFR estimations play a role in HFrEF prognosis without difference among the 6 most frequently used formulas. Furthermore, using eGFR calculated from the 6 different formulas in MECKI score did not significantly alter its strong prognostic power, highlighting MECKI reliability in risk stratification. - Exploring sex differences in mortality among acute myocardial infarction
Lorenzo Cangiano, Alice Bonomi, Nicola Cosentino, Olivia Leoni, Filippo Trombara, et al.
Open Heart, 2025
Background Women with acute myocardial infarction (AMI) experience higher mortality rates than men. This disparity is influenced by factors such as older age, greater comorbidity burden, atypical symptom presentation and delays in treatment. This study analysed patients with AMI (2003–2018) from the Lombardy Health Database (Italy) to examine sex differences in in-hospital and 1-year mortality and the role of age, percutaneous coronary intervention (PCI) and postdischarge therapy. Methods and results Among 263 564 patients with AMI (93 363 women, 170 201 men), primary and secondary endpoints were in-hospital and 1-year mortality, respectively. Path analysis evaluated the direct and indirect effects of sex on outcomes, incorporating age, PCI and postdischarge therapy as mediators. Women had higher in-hospital (10% vs 5%; p<0.0001) and 1-year mortality (24% vs 14%; p<0.0001) but were less likely to receive PCI (40% vs 61%; p<0.0001) and postdischarge therapy (dual antiplatelet therapy 53% vs 63%; ACE inhibitors/angiotensin receptor blockers 60% vs 64%; beta blockers 53% vs 61%; lipid-lowering drugs 45% vs 58%; p<0.0001 for all differences). After adjusting for age, major comorbidities, PCI and postdischarge treatment, mortality differences were no longer significant (adjusted OR 1.04; 95% CI 0.99 to 1.07 for in-hospital mortality) or even reversed (adjusted HR 0.94; 95% CI 0.92 to 0.96 for 1-year mortality). Path analysis showed that female sex directly contributed 12% to in-hospital mortality and 4% to 1-year mortality, while age and undertreatment accounted for most of the disparity (88% and 96%, respectively). Conclusion Women with AMI face higher mortality largely due to older age and undertreatment during hospitalisation and after discharge. Addressing these gaps could improve outcomes. - Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists
Nicola Cosentino, Filippo Trombara, Monica De Metrio, Chiara Molinari, Stefano Genovese, et al.
Pharmaceuticals, 2025
Coronary artery disease (CAD) and its acute manifestation, myocardial infarction (AMI), remain significant global health burdens, with a substantial impact on morbidity and mortality, especially in individuals with Type 2 Diabetes Mellitus (T2DM). The interaction between hyperglycemia, endothelial dysfunction, inflammation, and thrombosis creates a complex pathological environment that contributes to the progression of CAD and its acute complications, including AMI. Over recent years, there has been a shift in the therapeutic approach to CAD, especially in T2DM patients, where pharmacologic agents originally developed for glycemic control have demonstrated notable cardiovascular benefits beyond glucose regulation. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are at the forefront of this paradigm shift. Initially, these agents were designed to improve glycemic control, but their broader cardiovascular protective effects have become increasingly evident, particularly in patients with CAD. This review aims to provide an in-depth exploration of the mechanistic underpinnings of these agents, the clinical data supporting their cardiovascular benefits, and their potential role for patients with CAD. - Furosemide-hydration matching with RenalGuard® in decompensated heart failure: an alternative way to use diuretics and saline
Massimo Mapelli, Filippo Maria Rubbo, Jeness Campodonico, Nicola Cosentino, Giancarlo Marenzi, et al.
Esc Heart Failure, 2025 - Atrial Fibrillation Is Associated With Increased In-Hospital and 1-Year Mortality in Patients Receiving Hemodialysis With ST Elevation Myocardial Infarction: A Retrospective Cohort Study
Simonetta Genovesi, Giuseppe Regolisti, Alice Bonomi, Olivia Leoni, Arianna Galotta, et al.
Kidney Medicine, 2025 - Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients
Daniela Cardinale, Giancarlo Marenzi
Jacc Cardiooncology, 2025 - MINOCA and Type 2 mycardial infarction: Unveiling the hidden differences
Lorenzo Cangiano, Nicola Cosentino, Giancarlo Marenzi
International Journal of Cardiology, 2025 - Characteristics and outcomes of patients with cancer hospitalized with new onset acute heart failure
Giancarlo Marenzi, Daniela Cardinale, Nicola Cosentino, Filippo Trombara, Paolo Poggio, et al.
Esc Heart Failure, 2025 - Temporal trends (2003–2018) of in-hospital and 30-day mortality in patients hospitalized with acute heart failure
Giancarlo Marenzi, Nicola Cosentino, Livio Imparato, Filippo Trombara, Olivia Leoni, et al.
International Journal of Cardiology, 2025 - Tissue Factor, a Membrane-associated Marker of Platelet Activation, Predicts 5-year Cardiovascular Mortality in Coronary Artery Disease Patients
Marina Camera, Marta Brambilla, Nicola Cosentino, Alessia Becchetti, Patrizia Della Valle, et al.
Thrombosis and Haemostasis, 2025 - Deceived by the Fick principle: blood flow distribution in heart failure
Piergiuseppe Agostoni, Gaia Cattadori, Carlo Vignati, Anna Apostolo, Stefania Farina, et al.
European Journal of Preventive Cardiology, 2024 - The network of the EASY-NET programme: a contribution to knowledge on the effectiveness of audit&feedback
A. Acampora, L. Angelici, L. Deroma, Annarita Tullio, G. Ciccone, et al.
Epidemiologia E Prevenzione, 2024 - Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial
Felice Achilli, Stefano Maggiolini, Fabiana Madotto, Beatrice Bassetti, Francesco Gentile, et al.
Heart, 2024 - Whole-Blood Transcriptome Unveils Altered Immune Response in Acute Myocardial Infarction Patients with Aortic Valve Sclerosis
Luca Piacentini, Veronika A. Myasoedova, Mattia Chiesa, Chiara Vavassori, Donato Moschetta, et al.
Arteriosclerosis Thrombosis and Vascular Biology, 2024 - Vitamin D and cardiovascular diseases
Valentina Milazzo, Nicola Cosentino, Filippo Trombara, Giancarlo Marenzi
Advances in Food and Nutrition Research, 2024 - Prediction of In-Hospital Atrial Fibrillation After Acute Myocardial Infarction
Matteo Bulloni, Guadalupe García Isla, Pedro Moreno-Sánchez, Erica Rurali, Alice Bonesi, et al.
Computing in Cardiology, 2024 - Unstable angina: A clinical entity on the verge of extinction?
Claudia Lucci, Nicola Cosentino, Giancarlo Marenzi
International Journal of Cardiology, 2023 - Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
Filippo Trombara, Nicola Cosentino, Alice Bonomi, Monica Ludergnani, Paolo Poggio, et al.
Cardiovascular Diabetology, 2023
